Donor human milk versus formula for preventing necrotising enterocolitis in preterm infants: systematic review

W McGuire, M Y Anthony

METHODS
Prespecified inclusion criteria
Randomised and quasi-randomised controlled trials comparing enteral feeding with donor human milk versus formula milk in preterm (< 37 weeks gestation) or low birthweight (< 2.5 kg) infants were included. The allocated milk feed should have formed the entire enteral intake, not a supplement to the expressed breast milk of the mother. Trials in which parenteral nutritional support is available during the period of advancement of enteral feeds were acceptable, provided that the groups received similar treatment other than the type of milk feed. The following outcomes were considered:

- NEC, as defined and reported by individual trials;
- confirmed NEC, radiological confirmation showing gas in the portal venous system or free air in the abdomen, or when NEC is confirmed at surgery or autopsy.

Search strategy for identification of studies
The standard search strategy of the Cochrane Neonatal Review Group was used. This included electronic searches of the Cochrane Controlled Trials Register (CCTR; 2001, Issue 2), Medline (1966 to October 2001), and Embase (1980 to October 2001). No language restriction was applied. References in studies identified as relevant, and in previous reviews and standard textbooks of neonatal medicine and nutrition were examined.

The search strategy involved the following keywords, using the search fields of abstract, MeSH subject heading, exploded subject heading, publication type, registry number word, subject heading word, text word, and title: (1) “Infant-Newborn”/all subheadings; (2) infant*; (3) neonat*; (4) newborn; (5) prematur*; (6) preemie; (7) low birth weight; (8) (small or light) near3 (date* or gestational age); (9) LDW; (10) VLBW; (11) SGA; (12) growth restrict*; (13) growth retard*; (14) IUGR; (15) explode “Infant-Nutrition”/all subheadings; (16) explode “Feeding-Methods”/all subheadings; (17) milk; (18) breast near3 feed*; (19) breast near3 fed; (20) formula, (21) PT = “CLINICAL-TRIAL”.

Abbreviations: NEC, necrotising enterocolitis; RR, relative risk; CI, confidence interval; RD, risk difference
The title and abstract of studies identified by the above search strategy were screened by the first reviewer. The full text of the report of each study identified as of potential relevance was reviewed by both reviewers. The decision to include or exclude a specific study was made by consensus of these two reviewers. The criteria and standard methods of the Cochrane Neonatal Review Group were used to assess the methodological quality of the included trials. Quality of the trials was evaluated in terms of allocation concealment, blinding of parents or carers and assessors to intervention, and completeness of assessment in all randomised subjects. Additional information was requested from the authors of each trial to clarify methodology and results as necessary.

A data collection form was used to aid extraction of relevant information and data from each included study. Each reviewer extracted the data separately, compared data, and resolved differences by consensus. Effects were expressed as relative risk (RR) and 95% confidence interval (CI) and risk difference (RD) and 95% CI for a categorical data, fixed effect model for meta-analysis.

RESULTS

Description of studies

Eleven trials that appeared to be relevant were identified in the first round of screening. Four of these trials fulfilled the inclusion criteria and contributed to the meta-analysis.\(^1\)\(^{10}\)\(^{12}\) Table 1 gives details of the methods and quality assessment, and table 2 gives details of participant characteristics, interventions, and outcomes. Seven of the trials were excluded in the second round of screening, with complete agreement between the reviewers.\(^3\)\(^{18}\) Five of these trials (six reports) randomised preterm infants to feeding with donor human milk versus formula, but did not report NEC as an outcome.\(^3\)\(^{18}\) Two trials were non-randomised, although this was not clear from the title and abstract.\(^1\)\(^{19}\)

### Necrotising enterocolitis

None of the four included trials showed any statistically significant difference in the incidence of NEC. When the data from the trials were combined in a meta-analysis, we found a borderline statistically significant difference in the incidence of NEC: RR 0.34 (95% CI 0.12 to 0.99); RD −0.05 (95% CI −0.1 to 0.00) (fig 1).

### Confirmed necrotising enterocolitis

None of the four included trials showed a statistically significant difference in the incidence of confirmed NEC. In a combined meta-analysis we found a borderline statistically significant difference in the incidence of confirmed NEC: RR 0.25 (95% CI 0.06 to 0.98); RD −0.04 (95% CI −0.09 to 0.00) (fig 2).

In a post hoc analysis, we included the data from a trial in which infants received donor human milk or formula as a supplement to the expressed breast milk of the infant’s mother. The investigators did not find any significant difference in the incidence of NEC. When the data were combined with those of the previously included trials, the

| Table 1 Characteristics of included studies: methods |
|---|---|---|---|---|
| Trial (year published) | Method of randomisation | Allocation concealment | Blinding of intervention | Complete follow up | Blinding of outcome measurement |
| Gross (1983) | Random number table | Yes | No | Yes | Can’t tell |
| Lucas (1990) | Sealed envelopes | Yes | No | Yes | Can’t tell |
| Svenningsen (1982) | Not stated | Can’t tell | No | Yes | Can’t tell |
| Tyson (1983) | Sealed envelopes | Yes | No | Yes | Can’t tell |

| Table 2 Characteristics of included studies: participants, intervention, and outcome |
|---|---|---|---|---|
| Trial (year published) | Participants | Setting | Interventions | Outcomes (n/N) | Notes |
| Tyson (1983) | 81 very low birth weight infants, excluding infants with “any significant illness” or those who required ventilatory support at day 10 of life | Department of Pediatrics, University of Texas, Dallas, USA. Early 1980s | Donor human milk (N=37) versus calorie-enriched formula (N=44). | NEC (suspected and confirmed): Donor human milk: 0/37 Formula milk: 2/44 NEC (confirmed only): Donor human milk: 0/37 Formula milk: 1/44 | NEC reported as withdrawal criterion rather than outcome. Feeds allocated on the tenth day of life and continued until the infant reached a weight of 2000 g. |
meta-analysis did not find any significant difference in the incidence of NEC: RR 0.68 (95% CI 0.34 to 1.37); RD −0.02 (95% CI −0.05 to 0.01). However, we found a borderline significant difference in the incidence of confirmed NEC: RR 0.30 (95% CI 0.11 to 0.87); RD −0.03 (95% CI −0.06 to 0.00).

**DISCUSSION**

The data available from the included trials suggest that feeding with donor human milk rather than formula milk may reduce the incidence of NEC in preterm or low birthweight infants. NEC is three times less likely, and confirmed NEC is nine times less likely, in infants who were randomised to receive donor human milk rather than formula milk. Although the relative risk estimates were statistically significant, the risk difference estimates were not, and the overall effect is described as of borderline statistical significance. Consequently, the estimated number needed to treat (one case of confirmed NEC averted if 20 infants receive donor human milk) should be applied with caution. Moreover, in the included trials, parents or carers were not blind to the intervention because the threshold for investigation or diagnosis may be affected by knowledge of the type of milk received. About 900 infants would be required to participate in a large (about 30 centres with an established donor milk bank) pragmatic trial in order to detect the estimated size of effect found in this review (with 95% confidence and at 80% power).

**Figure 1** Relative risk of necrotising enterocolitis in infants randomised to donor human milk versus formula milk.

**Figure 2** Relative risk of confirmed necrotising enterocolitis in infants randomised to donor human milk versus formula milk.

Given the uncertainty about the clinical applicability of these findings, further studies should be undertaken. NEC remains a major cause of death and debility in preterm infants, and improved strategies for prevention are required. However, there are concerns about the nutritional adequacy of donor breast milk. Future studies would be able to compare growth, development, and adverse events in infants fed with nutrient fortified donor human milk versus formula milk. Implementing this intervention would require the re-establishment of donor milk banks that were closed in the 1980s, despite the lack of data to suggest a significant risk of transmission of HIV and other infectious agents via donor milk. The costs and feasibility of using donor human milk should be compared with those of other interventions that might reduce the incidence of NEC, such as the supplementation of formula milk with immunoglobulin. These trials should be undertaken in infants who are at very high risk of developing NEC, such as very low birthweight infants. Carers and assessors should be blind to the intervention because the threshold for investigation or diagnosis may be affected by knowledge of the type of milk received. About 900 infants would be required to participate in a large (about 30 centres with an established donor milk bank) pragmatic trial in order to detect the estimated size of effect found in this review (with 95% confidence and at 80% power).

**REFERENCES**

Donor human milk versus formula for preventing necrotising enterocolitis in preterm infants: systematic review

W McGuire and M Y Anthony

Arch Dis Child Fetal Neonatal Ed 2003 88: F11-F14
doi: 10.1136/fn.88.1.F11

Updated information and services can be found at:
http://fn.bmj.com/content/88/1/F11

These include:

References
This article cites 23 articles, 8 of which you can access for free at:
http://fn.bmj.com/content/88/1/F11#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/